This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowinsky, E. K. Articles by Tolcher, A. W. Search for Related Content PubMed PubMed Citation Articles by Rowinsky, E. K. Articles by Tolcher, A. W.

A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies

Eric K. Rowinsky, Jinee Rizzo, Leonel Ochoa, Chris H. Takimoto, Bahram Forouzesh, Garry Schwartz, Lisa A. Hammond, Amita Patnaik, Joseph Kwiatek, Andrew Goetz, Louis Denis, Jeffrey McGuire, Anthony W. Tolcher

From the Institute for Drug Development, Cancer Therapy, and Research Center; The University of Texas Health Science Center at San Antonio; Brooke Army Medical Center, San Antonio, TX; and Enzon Inc., Piscataway, NJ.

Address reprint requests to Eric K. Rowinsky, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX; email: erowinsk{at}saci.org.

Purpose: To assess the feasibility of administering camptothecin (CPT), the prototypic topoisomerase I inhibitor, as polyethylene glycol (PEG)-CPT, a macromolecule consisting of CPT conjugated to chemically modified PEG. The study also sought to determine the maximum-tolerated dose (MTD) of PEG-CPT, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity.

Patients and Methods: Patients with advanced solid malignancies were treated with escalating doses of PEG-CPT as a 1-hour intravenous (IV) infusion every 3 weeks. A modified continual reassessment method was used for dose-level assignment to determine the MTD, which was defined as the highest dose level at which the incidence of dose-limiting toxicity did not exceed 20%.

Results: Thirty-seven patients were treated with 144 courses of PEG-CPT at seven dose levels ranging from 600 to 8,750 mg/m². Severe myelosuppression was consistently experienced by heavily pretreated (HP) and minimally pretreated (MP) patients at the highest dose level evaluated, 8,750 mg/m², whereas both HP and MP patients tolerated repetitive treatment at 7,000 mg/m². Cystitis, nausea, vomiting, and diarrhea were also observed but were rarely severe. A partial response was noted in a patient with platinum- and etoposide-resistant small-cell lung carcinoma, and minor responses were noted in one patient each with adenocarcinoma of unknown primary type and osteosarcoma. The pharmacokinetics of free CPT were dose proportional. Free CPT accumulated slowly in plasma, with maximal plasma concentrations achieved at 23 ± 12.3 hours; the harmonic mean half-life (t_1/2) of free CPT was long (t_1/2, 77.46 ± 36.77 hours).

Conclusion: Clinically relevant doses of CPT can be delivered by administering PEG-CPT. The recommended dose for phase II studies in both MP and HP patients is 7,000 mg/m² as 1-hour IV every 3 weeks. The characteristics of the myelosuppressive effects of PEG-CPT, the paucity of severe nonhematologic toxicities with repetitive treatment, the preliminary antitumor activity noted, and the slow clearance of CPT enabling simulation of desirable pharmacokinetic parameters with a convenient single-dosing regimen warrant further disease-directed evaluations.

Presented in part at the Thirty-Sixth Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 15–18, 2000.

This article has been cited by other articles:

				X. Wang, L. Yang, Z. Chen, and D. M. Shin Application of Nanotechnology in Cancer Therapy and Imaging CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110. [Abstract] [Full Text] [PDF]

				J. Homsi, G. R. Simon, C. R. Garrett, G. Springett, R. De Conti, A. A. Chiappori, P. N. Munster, M. K. Burton, S. Stromatt, C. Allievi, et al. Phase I Trial of Poly-L-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies Clin. Cancer Res., October 1, 2007; 13(19): 5855 - 5861. [Abstract] [Full Text] [PDF]

				W. C. Zamboni Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents Clin. Cancer Res., December 1, 2005; 11(23): 8230 - 8234. [Full Text] [PDF]

				J. A. Posey III, M. W. Saif, R. Carlisle, A. Goetz, J. Rizzo, S. Stevenson, M. S. Rudoltz, J. Kwiatek, P. Simmons, E. K. Rowinsky, et al. Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas Clin. Cancer Res., November 1, 2005; 11(21): 7866 - 7871. [Abstract] [Full Text] [PDF]

				O. Soepenberg, M. J. A. de Jonge, A. Sparreboom, P. de Bruin, F. A. L. M. Eskens, G. de Heus, J. Wanders, P. Cheverton, M. P. Ducharme, and J. Verweij Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors Clin. Cancer Res., January 15, 2005; 11(2): 703 - 711. [Abstract] [Full Text] [PDF]

				K. Mross, H. Richly, N. Schleucher, S. Korfee, M. Tewes, M. E. Scheulen, S. Seeber, T. Beinert, M. Schweigert, U. Sauer, et al. A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors Ann. Onc., August 1, 2004; 15(8): 1284 - 1294. [Abstract] [Full Text] [PDF]